Midas Pharma and Capsulution NanoScience have entered into a long-term cooperation agreement, with contract manufacturing capacity and other services being provided in exchange for access to drug delivery technology.
The agreement follows on from joint feasibility studies into the use of Capsulution’s LBL Technology for delivering pharmaceuticals, which was regarded as a success by the companies.
Consequently they entered into an agreement, with Capsulution looking to benefit from access to the range of contract services offered by Midas.
Alexander Herrmann, chief financial officer of Capsulution, said: "We are very pleased that, with Midas, we have been able to acquire a very competent and reliable partner from the pharmaceutical industry.
“Our key competence is as always the development of innovative drug delivery systems for a targeted and secure application of the active pharmaceutical substance based upon our worldwide patented LBL Technology. On the other hand, so-called standard pharmaceutical services should be provided by a growing network of partners.”
Midas’ role within this network is to offer Capsulution’s pharmaceutical clients assistance with procurement of pharmaceutical substances, pharmaceutical contract manufacturing, international license projects or the creation of registration dossiers.
Capsulution’s LBL Tehcnology
As part of the agreement Midas is gaining access to Capsulution’s LBL Technology. This proprietary technology is a versatile drug delivery mechanism according to the two companies.
Capsulution claims that its LBL nanocapsules can be made in almost any size, loaded with a wide range of therapeutics and covered in surface molecules for targeted delivery.
In particular the technology is aimed at increasing the bioavailability of poorly water-soluble pharmaceuticals.
Through customisation of the technology Capsulution believes that LBL can be a useful tool for a wide array of therapeutics, leading to the company entering into numerous agreements to develop it for specific markets.
In addition to the deal with Midas Capsulution are collaborating with companies including EMC microcollections to create needle free injections, TheraKine for the treatment of ocular diseases and are even looking to use LBL in High Performance Liquid Chromatography (HPLC) through working with Advanced Materials Technology.
The capsules are created by building a polymer film by applying layer upon layer of oppositely charged self-assembling polyelectrolyte molecules, which are then formed into shells using electrostatic gravities.
This method of production allows for scaling-up to large batches, which ensures manufacturing costs remain low according to Capsulution.